AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, has received U.S. Food and Drug Administration approval as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, based on results from the DESTINY-Breast09 Phase III trial. The approval marks the first new frontline treatment in over a decade for this indication, following a 44% reduction in disease progression risk compared to the long-standing THP (taxane, trastuzumab, and pertuzumab) regimen.

What this approval changes for clinical practice and frontline treatment benchmarks

The FDA’s decision formally shifts the frontline standard of care in HER2-positive metastatic breast cancer from the well-entrenched THP regimen to a combination of trastuzumab deruxtecan and pertuzumab. This is a significant development, not just in regulatory terms, but in real-world treatment planning. Median progression-free survival (PFS) exceeded 40 months with Enhertu plus pertuzumab, versus under 27 months with THP—a duration gain that few modern oncology regimens can match.

This is not merely a marginal improvement. The DESTINY-Breast09 trial data showed that the risk of disease progression or death was reduced by 44%, with a hazard ratio of 0.56. From a therapeutic standpoint, this pushes the PFS curve into a new frontier—over three years of disease control in a metastatic setting, long considered a clinical ceiling for HER2-positive disease. Clinicians tracking the evolution of HER2-directed regimens have called this shift one of the most substantial seen since the introduction of trastuzumab itself.

How the DESTINY-Breast09 trial strengthens regulatory and clinical confidence

DESTINY-Breast09 was a well-powered, global, randomized Phase III study with over 1,150 patients enrolled across five continents. Its stratification by prior treatment status, hormone receptor status, and PIK3CA mutation gives additional weight to its subgroup analysis. The trial not only met its primary endpoint—blinded central review of PFS—but also demonstrated consistent benefit across clinical subgroups.

The statistical robustness (p<0.0001) and tight confidence intervals leave little room for regulatory hesitation. The trial also incorporated a monotherapy arm for trastuzumab deruxtecan, which remains blinded and will likely be the subject of future filings. However, it is the combination arm with pertuzumab that now defines the frontline approach.

Notably, the regulatory review process was expedited through the FDA’s Real-Time Oncology Review (RTOR) and Project Orbis, signaling international coordination and urgency. Regulatory watchers suggest this model is becoming the de facto route for high-impact oncology drugs, particularly where survival or disease progression endpoints show outsized benefit.

Why this combination may accelerate HER2 ADC dominance across solid tumors

Enhertu’s approval for this frontline metastatic breast cancer indication extends its momentum from prior settings, including the second-line HER2-positive metastatic, HER2-low breast cancer, and even HER2-mutant non-small cell lung cancer. The combination with pertuzumab now marks a strategic leap: embedding the ADC earlier in the treatment paradigm, with potential ripple effects across multiple tumor types.

AstraZeneca and Daiichi Sankyo appear to be executing a methodical vertical expansion of the Enhertu label across HER2-expressing cancers, a strategy that could eventually culminate in tumor-agnostic approvals. Industry analysts see this latest approval as a precursor to broader combination use with checkpoint inhibitors or sequential ADC regimens. Enhertu’s payload-linker stability and bystander effect continue to distinguish it from other ADCs in development.

What clinical adoption and payer dynamics could complicate uptake

While the data is compelling, real-world adoption hinges on pricing, toxicity management, and comparative cost-effectiveness. Although the safety profile of the Enhertu and pertuzumab combination was consistent with individual components and no new signals emerged, interstitial lung disease (ILD) remains a class effect of concern for ADCs of this type. Clinical oncologists may still prefer to start with the familiar THP regimen in frailer patients, especially those with pre-existing pulmonary conditions.

On the reimbursement front, the cost of antibody-drug conjugates remains a sensitive topic. Enhertu’s use as a 1st-line agent will now be under payer scrutiny, especially for patients with Medicare or Medicaid. The combination’s pricing will need to justify itself not only on efficacy but also on quality-adjusted life year (QALY) metrics and total treatment duration. If adoption lags, it will not be due to data gaps but due to system-level financial resistance.

The strategic upside for Daiichi Sankyo and AstraZeneca in oncology leadership

From a commercial perspective, this approval triggers a $150 million milestone payment from AstraZeneca to Daiichi Sankyo. Sales in the U.S. are booked by Daiichi Sankyo, a detail that reflects the complexity of the global co-commercialization agreement between the two companies. The long-term upside is enormous. According to internal estimates, around 10,000 patients are eligible annually for 1st-line HER2-positive metastatic treatment in the United States alone.

For AstraZeneca, this further cements its leadership position in breast cancer, adding to a portfolio that already includes the PARP inhibitor olaparib, AKT inhibitor capivasertib (Truqap), and the TROP2 ADC datopotamab deruxtecan (Datroway). The company’s broader strategy in oncology—redefining treatment classes and sequencing—gains more credibility with each Enhertu expansion.

Daiichi Sankyo, meanwhile, solidifies its identity as a top-tier ADC innovator. Enhertu is now approved in multiple lines across HER2-positive and HER2-low breast cancer, as well as in HER2-positive gastric and lung cancers. Regulatory watchers note that the consistency of data across these trials, combined with Daiichi’s proprietary DXd platform, positions the company to lead the next wave of ADC development and licensing deals.

What questions remain around future use, sequencing, and long-term resistance

One area where uncertainty persists is sequencing. With Enhertu now approved in both 1st-line and later lines, clinicians must grapple with how to space ADCs to avoid cumulative toxicity and resistance. No clear guidance yet exists on whether retreatment with Enhertu after progression on its frontline use will be clinically valid.

Additionally, the trial design of DESTINY-Breast09 did not include direct comparison with T-DXd monotherapy in the same setting, leaving some unanswered questions about the role of pertuzumab. The blinded monotherapy arm is still ongoing, and depending on its results, AstraZeneca and Daiichi Sankyo may pivot again.

Finally, with 25% to 30% of patients still not progressing beyond 1st-line therapy due to rapid disease course or adverse events, there is a limit to the real-world impact of even a groundbreaking drug. Clinical observers argue that deeper biomarker profiling—such as HER2 expression gradients or co-mutation patterns—may be required to further personalize treatment and avoid overtreatment.

  antibody-drug conjugates, AstraZeneca, Daiichi Sankyo, DESTINY-Breast09, Enhertu, HER2-positive metastatic breast cancer, oncology, pertuzumab, trastuzumab deruxtecan